GU Cancers Symposium: Predictive Biomarkers in Kidney Cancer
Certain genotypes may be used as both predictive and prognostic biomarkers for patients with localized and metastatic renal cell cancers, according to new study findings presented at the 2018 Genitourinary Cancers Symposium in San Francisco (Abstract 588). The study, led by Carmen Garrigós, PhD, of the Instituto de Biomedicina de Sevilla in Spain, confirms previous observations by Dr. Garrigós and colleagues about single nucleotide polymorphisms (SNPs) as predictive of survival in this patient population.
“This is particularly important in an era where multiple treatment options are available for this disease,” the investigators concluded.
Genotyping was performed on DNA isolated from paraffin-embedded tumor samples of 87 patients with localized (n = 66) and metastatic (n = 21) renal cell cancers. In those with localized cancer, the presence of allele C of rs307826 (FLT4 gene) seemed to correlate with a greater chance of relapse (P = .025) and shorter disease-free survival (21 vs. 35 months). Also, in the patients with localized disease, allele T of rs2227543 (IL8 gene) was associated with longer overall survival (14 vs. 3 months), whereas allele G of rs10013228 (KDR gene) was linked to worse overall survival (4 vs. 17 months). As for patients with metastatic disease, allele C of rs307826 (FLT4 gene) and allele A of rs9800958 (PRKAR1B) correlated with shorter progression-free survival (8 vs. 18 months and 8 vs. 17 months, respectively).